J. W. Valle, I. Borbath, and S. A. Khan, Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol, vol.27, pp.28-37, 2016.

J. Valle, H. Wasan, and D. H. Palmer, Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer, N Engl J Med, vol.362, pp.1273-1281, 2010.

B. Brieau, L. Dahan, and Y. De-rycke, Second-line chemotherapy for advanced biliary tract cancer after failure of the gemcitabine-platinum combination: A large multicenter study by the Association des Gastro-Enterologues Oncologues, Cancer, vol.121, pp.3290-3297, 2015.

L. Fornaro, S. Cereda, and G. Aprile, Multivariate prognostic factors analysis for second-line chemotherapy in advanced biliary tract cancer, Br J Cancer, vol.110, pp.2165-2169, 2014.

L. Fornaro, C. Vivaldi, and S. Cereda, Second-line chemotherapy in advanced biliary cancer progressed to first-line platinum-gemcitabine combination: a multicenter survey and pooled analysis with published data, J Exp Clin Cancer Res, vol.34, p.156, 2015.

B. J. Kim, C. Yoo, and K. P. Kim, Efficacy of fluoropyrimidine-based chemotherapy in patients with advanced biliary tract cancer after failure of gemcitabine plus cisplatin: retrospective analysis of 321 patients, Br J Cancer, vol.116, pp.561-567, 2017.

C. Neuzillet, C. Gardini, A. Brieau, and B. , Prediction of survival with secondline therapy in biliary tract cancer: Actualisation of the AGEO CT2BIL cohort and European multicentre validations, Eur J Cancer, vol.111, pp.94-106, 2019.

A. Lamarca, R. A. Hubner, D. Ryder, W. Valle, and J. W. , Second-line chemotherapy in advanced biliary cancer: a systematic review, Ann Oncol, vol.25, pp.2328-2338, 2014.

J. Adeva, B. Sangro, and M. Salati, Medical treatment for cholangiocarcinoma, Liver Int, vol.39, issue.1, pp.123-142, 2019.

Y. Zheng, X. Tu, and P. Zhao, A randomised phase II study of second-line XELIRI regimen versus irinotecan monotherapy in advanced biliary tract cancer patients progressed on gemcitabine and cisplatin, Br J Cancer, vol.119, pp.291-295, 2018.

A. Lamarca, D. H. Palmer, and H. S. Wasan, ABC-06 | A randomised phase III, multicentre, open-label study of Active Symptom Control (ASC) alone or ASC with oxaliplatin / 5-FU chemotherapy (ASC + mFOLFOX) for patients with locally advanced / metastatic biliary tract cancers (ABC) previously-treated with cisplatin/gemcitabine (CisGem) chemotherapy. ASCO meeting, 2019.

J. Ying and J. Chen, Combination versus mono-therapy as salvage treatment for advanced biliary tract cancer: A comprehensive meta-analysis of published data, Crit Rev Oncol Hematol, vol.139, pp.134-142, 2019.

M. Schemper and T. L. Smith, A note on quantifying follow-up in studies of failure time, Control Clin Trials, vol.17, pp.343-346, 1996.

N. I. Cherny, U. Dafni, and J. Bogaerts, ESMO-Magnitude of Clinical Benefit Scale version 1.1, Ann Oncol, vol.28, pp.2340-2366, 2017.

J. N. Primrose, R. P. Fox, and D. H. Palmer, Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study, Lancet Oncol, vol.20, pp.663-673, 2019.

S. Cereda, M. Milella, and S. Cordio, Capecitabine with/without mitomycin C: results of a randomized phase II trial of second-line therapy in advanced biliary tract adenocarcinoma, Cancer Chemother Pharmacol, vol.77, pp.109-114, 2016.

T. Sasaki, H. Isayama, and Y. Yashima, S-1 monotherapy in patients with advanced biliary tract cancer, Oncology, vol.77, pp.71-74, 2009.

T. Sasaki, H. Isayama, and Y. Nakai, Multicenter phase II study of S-1 monotherapy as second-line chemotherapy for advanced biliary tract cancer refractory to gemcitabine, Invest New Drugs, vol.30, pp.708-713, 2012.

E. Suzuki, M. Ikeda, and T. Okusaka, A multicenter phase II study of S-1 for gemcitabine-refractory biliary tract cancer, Cancer Chemother Pharmacol, vol.71, pp.1141-1146, 2013.

A. Vogel, V. Sahai, and A. Hollebecque, FIGHT-202: a phase 2 study of pemigatinib in patients (pts) with previously treated locally advanced or metastatic cholangiocarcinoma (CCA), ESMO meeting 2019 Abstract LBA 40

G. K. Abou-alfa, M. Mercade, T. Javle, and M. , ClarIDHy: A global, phase 3, randomized, double-blind study of ivosidenib (IVO) vs placebo in patients with advanced cholangiocarcinoma (CC) with an isocitrate dehydrogenase 1 (IDH1) mutation. ESMO meeting, 2019.

A. Drilon, T. W. Laetsch, and S. Kummar, Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children, N Engl J Med, vol.378, pp.731-739, 2018.

D. T. Le, J. N. Durham, and K. N. Smith, Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade, Science, vol.357, pp.409-413, 2017.

L. Verlingue, D. Malka, and A. Allorant, Precision medicine for patients with advanced biliary tract cancers: An effective strategy within the prospective MOSCATO-01 trial, Eur J Cancer, 2017.

, 95%CI: 0.701 to 1.250, p=0.6532) (A), subgroup of patients with ECOG, 95%CI: 0.637 to 1.586, p=0.9816 ) (C). Italian (GICO) cohort: overall population

, 95%CI: 0.717 to 1.319 for irinotecan doublet vs. monotherapy, p=0.6846) (A), subgroup of patients with PS 0-1 (HR: 1.007, 95%CI: 0.636 to 1.595 for platinum doublet vs, 95%CI: 0.615 to 1.928 for platinum doublet vs. monotherapy and HR: 0.969, 95%CI: 0.596 to 1.576 for irinotecan doublet vs. monotherapy, p=0.9048) (C). Italian (GICO) cohort: overall population, vol.2